RESOURCES

/

FIND A SPECIALIST

/

CONTACT

The FDA Needs to Hear Your Voice

The FDA is currently reviewing a potential treatment for focal segmental glomerulosclerosis (FSGS). Sign our letter to the FDA to ensure that the lived experiences of patients and caregivers are part of this decision. Your journey with FSGS matters. Your voice matters. And right now, it matters more than ever that you are heard. Sign NephCure's letter to the FDA by 2/18. 

Sign now

Lawrence B. Holzman, M.D.

Chief, Renal Electrolyte and Hypertension

Division Professor of Medicine, Perelman School of Medicine, University of Pennsylvania

Dr. Lawrence B. Holzman is an NIH-funded laboratory researcher, well recognized for his investigations of mechanisms of cell signaling and podocyte biology. His work has contributed importantly to understanding the mechanisms that govern podocyte cytoskeletal architecture, and his research has led to multiple discoveries. Dr. Holzman is affiliated with numerous professional organizational fellowships, including the American Society of Nephrologists, the American Heart Association Kidney Council, the American Association for the Advancement of Science, and the National Kidney Foundation Science Committee.

Dr. Holzman received his M.D. training from the New Jersey Medical School, completed a residency at The Hospital of the Medical College of Pennsylvania, and completed a fellowship in nephrology at the University of Michigan. Dr. Holzman has served as a research mentor to several fellows who have gone on to achieve academic positions in the United States and Germany.

Selected Publications
Bonventre JV, Boulware LE, Dember LM, Freedman BI, Furth SL, Holzman LB, Ketchum CJ, Little MH, Mehrotra R, Moe SM, Sands JM, Sedor JR, Somlo S, Star RA, Rys-Sikora KE. The Kidney Research National Dialogue: Gearing Up to Move Forward. Clin J Am Soc Nephrol. 2014.

Wiggins RC, Alpers CE, Holzman LB, He JC, Salant DJ, Chugh SS, Natarajan R, Trachtman H, Brasile L, Star RA, Rys-Sikora KE, Moxey-Mims MM, Flessner MF; Kidney Research National Dialogue. Glomerular disease: Looking beyond pathology. Clin J Am Soc Nephrol. 2014; 9(6), 1138-1140.

Arif E, Rathore YS, Kumari B, Ashish F, Wong HN, Holzman LB, Nihalani D. Slit diaphragm protein Neph1 and its signaling: A novel therapeutic target for protection of podocytes against glomerular injury. J Biol Chem. 2014; 289(14), 9502-9518.

Tian X, Kim JJ, Monkley SM, Gotoh N, Nandez R, Soda K, Inoue K, Balkin DM, Hassan H, Son SH, Lee Y, Moeckel G, Calderwood DA, Holzman LB, Critchley DR, Zent R, Reiser J, Ishibe S. Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance. J Clin Invest. 2014; 124(3), 1098-1113.

Blattner SM, Hodgin JB, Nishio M, Wylie SA, Saha J, Soofi AA, Vining C, Randolph A, Herbach N, Wanke R, Atkins KB, Gyung Kang H, Henger A, Brakebusch C, Holzman LB, Kretzler M. Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int. 2013; 84(5), 920-930.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013; 83(4), 749-756.

George B, Holzman LB. Signaling from the podocyte intercellular junction to the actin cytoskeleton. Semin Nephrol. 2012; 32(4), 307-318.

Fan X, Li Q, Pisarek-Horowitz A, Rasouly HM, Wang X, Bonegio RG, Wang H, McLaughlin M, Mangos S, Kalluri R, Holzman LB, Drummond IA, Brown D, Salant DJ, Lu W. Inhibitory effects of Robo2 on nephrin: a crosstalk between positive and negative signals regulating podocyte structure. Cell Rep. 2012; 2(1), 52-61.

Philadelphia, PA

Related News

NEWS

Letter to the NephCure Community: Update on FDA Decision About Sparsentan for FSGS

NEWS

NephCure Unveils New Mission Focusing on New Era of Access for Rare Kidney Disease Patients

NEWS

The FDA Grants Accelerated Approval to VOYXACT, a New Treatment Option for Adults with IgA Nephropathy

NEWS

NephCure Wins Silver at the Fifth Annual Anthem Awards for Kidney Month Campaign

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.